b'In adult patients with CKD associated with T2DWith KERENDIA, a di\x10erent pathway leads to di\x10erent possibilities1,2KERENDIA o\x10ers a di\x10erent path forward KERENDIA is the \x11 rst and only selective MRA with a nonsteroidal structure KERENDIA blocks MR overactivation, which is thought to contribute to in\x7f ammationand \x11 brosis that can lead to CKD progressionIn adults with CKD associated with T2D, KERENDIA is proven to slow CKD progression and reduce CV riskLearn more about KERENDIA and the FIDELIO-DKD trialINDICATION: KERENDIA is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)IMPORTANT SAFETY INFORMATION MOST COMMON ADVERSE REACTIONS: USE IN SPECIFIC POPULATIONS Adverse reactions reported in 1%Lactation: CONTRAINDICATIONS:Avoid breastfeeding duringConcomitant use with strong CYP3A4 inhibitorsof patients on KERENDIA and moretreatment with KERENDIA and for 1 dayPatients with adrenal insuciencyfrequently than placebo: hyperkalemiaafter treatment (18.3% vs. 9%), hypotension (4.8% vs.Hepatic Impairment:WARNINGS AND PRECAUTIONS: 3.4%), and hyponatremia (1.4% vs. 0.7%)Avoid use of Hyperkalemia:KERENDIA can causeKERENDIA in patients with severe hepatic hyperkalemia. The risk for developingDRUG INTERACTIONS: impairment (Child Pugh C) and consider hyperkalemia increases with decreasing kidneyStrong CYP3A4 Inhibitors: additional serum potassium monitoringConcomitantwith moderate hepatic impairmentfunction and is greater in patients with higheruse of KERENDIA with strong CYP3A4(Child Pugh B) baseline potassium levels or other risk factorsinhibitors is contraindicated. Avoid for hyperkalemia. Measure serum potassiumconcomitant intake of grapefruit or and eGFR in all patients before initiation ofgrapefruit juice Please read the Brief Summary of the treatment with KERENDIA and dose accordingly.Moderate and Weak CYP3A4 Inhibitors: KERENDIA Prescribing Information on the Do not initiate KERENDIA if serum potassium Monitor serum potassium during drugfollowing pages.is 5.0 mEq/L initiation or dosage adjustment of either Measure serum potassium periodically during KERENDIA or the moderate or weakCKD=chronic kidney disease; CV=cardiovascular; treatment with KERENDIA and adjust doseCYP3A4 inhibitor and adjust KERENDIAMR=mineralocorticoid receptor; MRA=mineralocorticoid accordingly. More frequent monitoring may bedosage as appropriatereceptor antagonist; T2D=type 2 diabetes.necessary for patients at risk for hyperkalemia,Strong and Moderate CYP3A4 References: 1. KERENDIA [prescribingincluding those on concomitant medicationsInducers: information]. Whippany, NJ: Bayer HealthCare 2021 Bayer. All rights reserved. BAYER, the Bayer Cross,Avoid concomitant use of that impair potassium excretion or increaseKERENDIA with strong or moderatePharmaceuticals, Inc; July 2021. 2. Bakris GL and KERENDIA are registered trademarks of Bayer.serum potassium CYP3A4 inducers et al. N Engl J Med. 2020;383(23):2219-2229. MAC-KER-US-0002-1 11/21'